PathAI AISight, AIM-PD-L1 NSCLC RUO Algorithm
PathAI has launched its AISight digital pathology platform along with its AIM-PD-L1 NSCLC RUO Algorithm in an early access program. AISight was designed with input from more than 200 pathologists and can be used by physicians, academic institutions, biopharma companies, and contract research organizations to support artificial intelligence-driven research. The AIM-PD-L1 NSCLC RUO algorithm analyzes non-small cell lung cancer surgical specimens and provides quantification and visualizations of PD-L1 positivity on tumor and immune cells. It is intended for use in immune oncology research applications and was trained on a real-world dataset of more than 5,000 samples.